Healthcare · Industry
Biotechnology - List & Prices (608 stocks)
| Company | Ticker | Price | Mkt cap | P/E | Div yield |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. | MLYS | $21.10 | $1.87B | — | |
| Zenas BioPharma, Inc. | ZBIO | $28.08 | $1.83B | — | |
| ADARx Pharmaceuticals, Inc. | ADRX | $17.13 | $1.83B | — | |
| Palvella Therapeutics, Inc. | PVLA | $126.58 | $1.82B | — | |
| Trevi Therapeutics, Inc. | TRVI | $12.77 | $1.82B | — | |
| Novavax, Inc. | NVAX | $11.01 | $1.82B | — | |
| Maze Therapeutics, Inc. | MAZE | $32.58 | $1.81B | — | |
| Vir Biotechnology, Inc. | VIR | $10.57 | $1.79B | — | |
| Braveheart Bio, Inc. | BRVE | $21.04 | $1.74B | — | |
| UroGen Pharma Ltd. | URGN | $35.48 | $1.73B | — | |
| Absci Corporation | ABSI | $10.04 | $1.72B | — | |
| Biohaven Ltd. | BHVN | $11.75 | $1.71B | — | |
| Nuvation Bio Inc. | NUVB | $4.85 | $1.70B | — | |
| Generate Biomedicines, Inc. | GENB | $13.11 | $1.68B | — | |
| Kailera Therapeutics, Inc. | KLRA | $12.92 | $1.67B | — | |
| Mesoblast Limited | MESO | $12.83 | $1.67B | — | |
| Stoke Therapeutics, Inc. | STOK | $25.68 | $1.66B | — | |
| Immunocore Holdings plc | IMCR | $32.09 | $1.65B | — | |
| Intellia Therapeutics, Inc. | NTLA | $11.65 | $1.63B | — | |
| Hemab Therapeutics Holdings, Inc. | COAG | $35.34 | $1.60B | — | |
| uniQure N.V. | QURE | $22.69 | $1.57B | — | |
| Ultragenyx Pharmaceutical Inc. | RARE | $15.92 | $1.57B | — | |
| Structure Therapeutics Inc. | GPCR | $22.01 | $1.57B | — | |
| First Tracks Biotherapeutics, Inc. | TRAX | $42.77 | $1.53B | — | |
| Ascentage Pharma Group Internat | AAPG | $16.34 | $1.53B | — | |
| Innoviva, Inc. | INVA | $20.91 | $1.51B | 4.9 | — |
| Korsana Biosciences, Inc. | KRSA | $32.54 | $1.48B | — | |
| Inhibrx Biosciences, Inc. | INBX | $98.19 | $1.45B | — | |
| ORIC Pharmaceuticals, Inc. | ORIC | $13.85 | $1.44B | — | |
| AnaptysBio, Inc. | ANAB | $47.94 | $1.43B | — | |
| Ocular Therapeutix, Inc. | OCUL | $6.48 | $1.42B | — | |
| Tyra Biosciences, Inc. | TYRA | $20.60 | $1.42B | — | |
| Taysha Gene Therapies, Inc. | TSHA | $4.12 | $1.34B | — | |
| Damora Therapeutics, Inc. | DMRA | $21.53 | $1.33B | — | |
| Nanobiotix S.A. | NBTX | $25.83 | $1.32B | — | |
| Nektar Therapeutics | NKTR | $38.27 | $1.31B | — | |
| GH Research PLC | GHRS | $18.91 | $1.30B | — | |
| LB Pharmaceuticals Inc | LBRX | $39.23 | $1.27B | — | — |
| Alpha Tau Medical Ltd. | DRTS | $13.48 | $1.25B | — | |
| Silence Therapeutics plc | SLN | $19.67 | $1.22B | — | |
| Bicara Therapeutics Inc. | BCAX | $17.91 | $1.21B | — | |
| Rapport Therapeutics, Inc. | RAPP | $25.06 | $1.20B | — | |
| Kardigan, Inc. | KARD | $12.85 | $1.20B | — | |
| Omeros Corporation | OMER | $16.26 | $1.18B | 13.3 | — |
| Syndax Pharmaceuticals, Inc. | SNDX | $13.15 | $1.17B | — | |
| Immatics N.V. | IMTX | $7.69 | $1.17B | — | |
| Vor Biopharma Inc. | VOR | $18.94 | $1.12B | — | — |
| Avalyn Pharma Inc. | AVLN | $25.11 | $1.11B | — | |
| Replimune Group, Inc. | REPL | $11.72 | $1.10B | — | |
| Latigo Biotherapeutics, Inc. | LTGO | $16.34 | $1.08B | — |
Mineralys Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.87B
- P/E
- unprofitable
Zenas BioPharma, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.83B
- P/E
- unprofitable
ADARx Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.83B
- P/E
- unprofitable
Palvella Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.82B
- P/E
- unprofitable
Trevi Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.82B
- P/E
- unprofitable
Novavax, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.82B
- P/E
- unprofitable
Maze Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.81B
- P/E
- unprofitable
Vir Biotechnology, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.79B
- P/E
- unprofitable
Braveheart Bio, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.74B
- P/E
- unprofitable
UroGen Pharma Ltd.
Healthcare / Biotechnology
- Market Cap
- $1.73B
- P/E
- unprofitable
Absci Corporation
Healthcare / Biotechnology
- Market Cap
- $1.72B
- P/E
- unprofitable
Biohaven Ltd.
Healthcare / Biotechnology
- Market Cap
- $1.71B
- P/E
- unprofitable
Nuvation Bio Inc.
Healthcare / Biotechnology
- Market Cap
- $1.70B
- P/E
- unprofitable
Generate Biomedicines, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.68B
- P/E
- unprofitable
Kailera Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.67B
- P/E
- unprofitable
Mesoblast Limited
Healthcare / Biotechnology
- Market Cap
- $1.67B
- P/E
- unprofitable
Stoke Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.66B
- P/E
- unprofitable
Immunocore Holdings plc
Healthcare / Biotechnology
- Market Cap
- $1.65B
- P/E
- unprofitable
Intellia Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.63B
- P/E
- unprofitable
Hemab Therapeutics Holdings, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.60B
- P/E
- unprofitable
uniQure N.V.
Healthcare / Biotechnology
- Market Cap
- $1.57B
- P/E
- unprofitable
Ultragenyx Pharmaceutical Inc.
Healthcare / Biotechnology
- Market Cap
- $1.57B
- P/E
- unprofitable
Structure Therapeutics Inc.
Healthcare / Biotechnology
- Market Cap
- $1.57B
- P/E
- unprofitable
First Tracks Biotherapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.53B
- P/E
- unprofitable
Ascentage Pharma Group Internat
Healthcare / Biotechnology
- Market Cap
- $1.53B
- P/E
- unprofitable
Innoviva, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.51B
- P/E
- 4.9
Korsana Biosciences, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.48B
- P/E
- unprofitable
Inhibrx Biosciences, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.45B
- P/E
- unprofitable
ORIC Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.44B
- P/E
- unprofitable
AnaptysBio, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.43B
- P/E
- unprofitable
Ocular Therapeutix, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.42B
- P/E
- unprofitable
Tyra Biosciences, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.42B
- P/E
- unprofitable
Taysha Gene Therapies, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.34B
- P/E
- unprofitable
Damora Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.33B
- P/E
- unprofitable
Nanobiotix S.A.
Healthcare / Biotechnology
- Market Cap
- $1.32B
- P/E
- unprofitable
Nektar Therapeutics
Healthcare / Biotechnology
- Market Cap
- $1.31B
- P/E
- unprofitable
GH Research PLC
Healthcare / Biotechnology
- Market Cap
- $1.30B
- P/E
- unprofitable
LB Pharmaceuticals Inc
Healthcare / Biotechnology
- Market Cap
- $1.27B
Alpha Tau Medical Ltd.
Healthcare / Biotechnology
- Market Cap
- $1.25B
- P/E
- unprofitable
Silence Therapeutics plc
Healthcare / Biotechnology
- Market Cap
- $1.22B
- P/E
- unprofitable
Bicara Therapeutics Inc.
Healthcare / Biotechnology
- Market Cap
- $1.21B
- P/E
- unprofitable
Rapport Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.20B
- P/E
- unprofitable
Kardigan, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.20B
- P/E
- unprofitable
Omeros Corporation
Healthcare / Biotechnology
- Market Cap
- $1.18B
- P/E
- 13.3
Syndax Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.17B
- P/E
- unprofitable
Immatics N.V.
Healthcare / Biotechnology
- Market Cap
- $1.17B
- P/E
- unprofitable
Vor Biopharma Inc.
Healthcare / Biotechnology
- Market Cap
- $1.12B
Avalyn Pharma Inc.
Healthcare / Biotechnology
- Market Cap
- $1.11B
- P/E
- unprofitable
Replimune Group, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.10B
- P/E
- unprofitable
Latigo Biotherapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.08B
- P/E
- unprofitable
Showing 101–150 of 608 · ranked by market capitalization
Where the trailing year was a loss, P/E appears as “unprofitable”; a dash is missing data.